Pi Guoliang, He Hanping, Bi Jianping, Li Ying, Li Yanping, Zhang Yong, Wang Mingwei, Han Guang, Lin Chi
Department of Radiation Oncology Department of Pathology, Hubei Cancer Hospital Department of Oncology, Renmin Hospital of Wuhan University, Wuhan, China Department of Radiation Oncology, University of Nebraska Medical Center, Omaha, NE.
Medicine (Baltimore). 2016 Oct;95(40):e5077. doi: 10.1097/MD.0000000000005077.
Currently, the options are limited for the treatment of patients who have failed 2 lines of chemotherapy for advanced lung squamous cell carcinoma (SCC). Recently, nivolumab, a fully human IgG4 programmed death 1 immune checkpoint inhibitor antibody, was approved to treat patients with advanced stage, relapsed/refractory lung SCC. Although nivolumab has demonstrated antitumor activity with survival benefit in Caucasian patients, its efficacy in Asian patients is unknown.
In this report, we describe a Chinese patient with relapsed advanced stage lung SCC who had an excellent response to nivolumab after only 2 doses without any adverse effects. Immunohistochemical analysis indicated the tumor was stained positive for programmed death-ligand 1.
To our knowledge, this is the first report of satisfactory efficacy of short-term nivolumab treatment in a Chinese patient with relapsed advanced-stage lung SCC. Further clinical trials in Asian countries are needed to test whether nivolumab immunotherapy is a safe and effective treatment for Asian patients with lung SCC.
目前，对于晚期肺鳞状细胞癌（SCC）经二线化疗失败的患者，治疗选择有限。最近，纳武单抗，一种全人源IgG4程序性死亡1免疫检查点抑制剂抗体，被批准用于治疗晚期、复发/难治性肺SCC患者。尽管纳武单抗在高加索患者中已显示出抗肿瘤活性并具有生存获益，但其在亚洲患者中的疗效尚不清楚。
在本报告中，我们描述了一名复发性晚期肺SCC中国患者，该患者仅接受2剂纳武单抗治疗后即有出色反应且无任何不良反应。免疫组化分析表明肿瘤程序性死亡配体1染色呈阳性。
据我们所知，这是关于纳武单抗短期治疗一名复发性晚期肺SCC中国患者取得满意疗效的首例报告。需要在亚洲国家进行进一步的临床试验，以检验纳武单抗免疫疗法对亚洲肺SCC患者是否为一种安全有效的治疗方法。
